PT  - JOURNAL ARTICLE
AU  - Sándor P. Manninger
AU  - Leslie L. Muldoon
AU  - Gary Nesbit
AU  - Tulio Murillo
AU  - Paula M. Jacobs
AU  - Edward A. Neuwelt
TI  - An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions
DP  - 2005 Oct 01
TA  - American Journal of Neuroradiology
PG  - 2290--2300
VI  - 26
IP  - 9
4099  - http://www.ajnr.org/content/26/9/2290.short
4100  - http://www.ajnr.org/content/26/9/2290.full
SO  - Am. J. Neuroradiol.2005 Oct 01; 26
AB  - BACKGROUND AND PURPOSE: Iron oxide–based contrast agents have been investigated as more specific MR imaging agents for central nervous system (CNS) inflammation. Ferumoxtran-10 is a virus-size nanoparticle, taken up by reactive cells, that allows visualization of the phagocytic components of CNS lesions. Ferumoxtran-10 was compared with standard gadolinium-enhanced MR images in this exploratory trial to assess its potential in evaluation of CNS lesions with inflammatory aspects, including lymphoma, multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and vascular lesions.METHODS: Twenty-three patients with different types of intracranial “inflammatory” lesions underwent standard brain MR with and without gadolinium, followed an average of 10 days later by a ferumoxtran-10 scan. Patients were imaged 24 hours after infusion of 2.6 mg/kg ferumoxtran-10. All MR images were evaluated subjectively by 4 investigators for a difference in enhancement patterns, which could be useful in differential diagnoses.RESULTS: In 5 cases, (one ADEM, 2 stroke, one cavernous venous vascular malformation, one primary central nervous lymphoma) the ferumoxtran-10 scan showed higher signal intensity, larger area of enhancement, or new enhancing areas compared with gadolinium. Most MS patients showed less enhancement with ferumoxtran-10 than with gadolinium.CONCLUSION: Ferumoxtran-10 showed different enhancement patterns in a variety of CNS lesions with inflammatory components in comparison to gadolinium. The impact of timing and therapy need further evaluation to better assess ferumoxtran-10 in addition to gadolinium as contrast agents for use in diagnosis and monitoring therapy in patients with CNS inflammatory lesions.